JP2021522802A5 - - Google Patents

Info

Publication number
JP2021522802A5
JP2021522802A5 JP2020561923A JP2020561923A JP2021522802A5 JP 2021522802 A5 JP2021522802 A5 JP 2021522802A5 JP 2020561923 A JP2020561923 A JP 2020561923A JP 2020561923 A JP2020561923 A JP 2020561923A JP 2021522802 A5 JP2021522802 A5 JP 2021522802A5
Authority
JP
Japan
Prior art keywords
composition according
treatment period
compound
hcv
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561923A
Other languages
English (en)
Japanese (ja)
Other versions
JP7279081B2 (ja
JP2021522802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031044 external-priority patent/WO2019217369A1/en
Publication of JP2021522802A publication Critical patent/JP2021522802A/ja
Publication of JP2021522802A5 publication Critical patent/JP2021522802A5/ja
Application granted granted Critical
Publication of JP7279081B2 publication Critical patent/JP7279081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561923A 2018-05-08 2019-05-07 Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法 Active JP7279081B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668467P 2018-05-08 2018-05-08
US62/668,467 2018-05-08
PCT/US2019/031044 WO2019217369A1 (en) 2018-05-08 2019-05-07 Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect

Publications (3)

Publication Number Publication Date
JP2021522802A JP2021522802A (ja) 2021-09-02
JP2021522802A5 true JP2021522802A5 (enExample) 2022-05-13
JP7279081B2 JP7279081B2 (ja) 2023-05-22

Family

ID=66625315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561923A Active JP7279081B2 (ja) 2018-05-08 2019-05-07 Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法

Country Status (7)

Country Link
US (1) US12005120B2 (enExample)
EP (1) EP3790972A1 (enExample)
JP (1) JP7279081B2 (enExample)
CN (1) CN112400020B (enExample)
CA (1) CA3099698A1 (enExample)
TW (1) TWI854980B (enExample)
WO (1) WO2019217369A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113718024A (zh) * 2020-05-26 2021-11-30 深圳市血液中心 血浆miRNA标志物及其应用
CA3246334A1 (en) * 2022-03-25 2023-09-28 Shanghai Hansoh Biomedical Co., Ltd. BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED ADMINISTRATION OF THERAPEUTIC AGENTS

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10503364A (ja) 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
JP2000501414A (ja) 1995-11-22 2000-02-08 ザ・ジョンズ・ホプキンス・ユニバーシティー 生体分子の細胞取り込みを高めるリガンド
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
IL148916A0 (en) 1999-10-04 2002-09-12 Exiqon As Design of high affinity rnase h recruiting oligonucleotide
AU3041701A (en) 1999-12-23 2001-07-09 Exiqon A/S Therapeutic uses of lna-modified oligonucleotides
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2002043771A2 (en) 2000-12-01 2002-06-06 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
CN1344803A (zh) 2001-09-27 2002-04-17 吴昌 核酸靶分子选择及扩增方法
JP4597976B2 (ja) 2003-04-17 2010-12-15 アルナイラム ファーマシューティカルズ インコーポレイテッド 修飾ｉＲＮＡ剤
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
JP4642775B2 (ja) 2003-12-23 2011-03-02 サンタリス ファーマ アー／エス Ｂｃｌ−２のモデュレーションのためのオリゴマー化合物
WO2006078278A2 (en) 2004-04-27 2006-07-27 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
PT1747023E (pt) 2004-05-04 2011-04-11 Univ Leland Stanford Junior Métodos e composições para reduzir quantidades de genoma viral numa célula alvo
CA2574603C (en) 2004-08-04 2014-11-04 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US20090203132A1 (en) 2004-09-09 2009-08-13 Swayze Eric E Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US20120122801A1 (en) 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
JP2008527993A (ja) 2005-01-24 2008-07-31 アヴァリス・アクチエボラーグ 特異性及び送達の改善のためのｓｉＲＮＡ分子、ｓｈＲＮＡ分子又はアンチセンス分子及び機能的実体を含む複合体
EP1919512B1 (en) 2005-08-10 2014-11-12 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
DK1931780T3 (en) 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
WO2007027775A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Methods for use in modulating mir-122a
US8129515B2 (en) 2006-01-27 2012-03-06 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
EP2261333B1 (en) 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
WO2008132234A2 (en) 2007-05-01 2008-11-06 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
ES2463665T3 (es) 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
KR20100110298A (ko) 2007-11-26 2010-10-12 산타리스 팔마 에이/에스 안드로겐 수용체를 표적화하는 ｌｎａ 길항제
CN102006890A (zh) 2007-12-04 2011-04-06 阿尔尼拉姆医药品有限公司 靶向脂质
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010076248A1 (en) 2008-12-31 2010-07-08 Santaris Pharma A/S Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
AU2010258875A1 (en) 2009-06-08 2012-01-19 Miragen Therapeutics Chemical modification motifs for miRNA inhibitors and mimetics
EP2512491B1 (en) 2009-10-16 2017-10-11 Glaxo Group Limited Hbv antisense inhibitors
EP3023495B1 (en) 2010-02-24 2019-05-08 Arrowhead Pharmaceuticals, Inc. Compositions for targeted delivery of sirna
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011130458A2 (en) 2010-04-13 2011-10-20 John Rossi Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use
WO2012007477A1 (en) 2010-07-12 2012-01-19 Santaris Pharma A/S Anti hcv oligomers
CA2812046A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. Modified irna agents
BR112013013434A2 (pt) 2010-12-17 2016-08-16 Arrowhead Res Corp metade que tem por alvo modulador fármaco cinético em cacho de galactose para sirna
ES2605990T3 (es) 2010-12-29 2017-03-17 F. Hoffmann-La Roche Ag Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
WO2012148952A1 (en) 2011-04-25 2012-11-01 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
EP2722388B1 (en) 2011-06-16 2017-08-09 Nippon Steel & Sumikin Eco-Tech Corporation Nucleic acid probe for assaying nucleic acids
KR20140051271A (ko) 2011-06-23 2014-04-30 스텔라 에이피에스 Hcv 조합 치료
US20140213632A1 (en) 2011-06-30 2014-07-31 Stella Aps HCV Combination Therapy
JP2014520772A (ja) 2011-06-30 2014-08-25 ステラ・アンパルトセルスカブ Ｈｃｖ併用療法
EP3640332A1 (en) * 2011-08-29 2020-04-22 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
AU2012334214A1 (en) 2011-11-07 2014-05-22 Roche Innovation Center Copenhagen A/S Prognostic method for checking efficacy of micro RNA-122 inhibitors in HCV+ patients
WO2013068348A1 (en) 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
EP2900822B1 (en) 2012-09-26 2021-11-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligomers with improved off-target profile
SG10201804331TA (en) 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
US20150368642A1 (en) 2013-01-30 2015-12-24 Hoffmann-La Roche Inc. Lna oligonucleotide carbohydrate conjugates
WO2014118272A1 (en) * 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
CN105164261B (zh) 2013-05-01 2022-03-18 莱古路斯治疗法股份有限公司 用于增强的细胞摄取的化合物和方法
EP2992095B1 (en) 2013-05-01 2019-01-09 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-122
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use

Similar Documents

Publication Publication Date Title
Gentile et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir
JP2008518943A5 (enExample)
JP2010503396A5 (enExample)
JP2021521118A5 (enExample)
AR079555A1 (es) Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv)
Bourlière et al. Sofosbuvir as backbone of interferon free treatments
CN108712905B (zh) 抗肝肿瘤病毒剂
WO2010031832A9 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
JP2016518842A5 (enExample)
TW200815384A (en) Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
KR20120139699A (ko) Ｃ형 간염 바이러스 감염의 치료 요법
JP2013540112A (ja) Ｈｃｖ感染を治療するための併用療法
JP2011522862A (ja) テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法
US10471048B2 (en) Thienopyridine derivative for the treatment of hepatitis C infections
US20130028865A1 (en) Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
WO2014033668A2 (en) Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
JP2021523129A5 (enExample)
Garg et al. Management of HCV infection: current issues and future options
Amblard et al. Nucleoside Antiviral Agents for HCV: what's Left to Do?
Reviriego Daclatasvir dihydrochloride
US10201541B1 (en) Compositions and methods for treating HCV
US20130273003A1 (en) Therapies for Treating Hepatitis C Virus Infection
JP2017514834A (ja) Ｈｃｖ感染症を治療するための組合せ療法
Kaur et al. Emerging therapies in pipeline for chronic hepatitis C
HK1131339A1 (en) Prophylactic or therapeutic agent for viral disease